CELLINK announces an increase in number of shares and votes

Report this content

The number of shares and votes in CELLINK AB (publ) (“CELLINK”) have increased as a result of an issue in kind of 262,320 shares of series B which was carried out as a part of the financing for the acquisition of Discover Echo Inc. The Board of Directors resolved on an issue in kind on June 30, 2021 in accordance with the authorization from the Annual General Meeting held on April 26, 2021.

Further, 349,000 warrants were exercised pursuant to CELLINK’s warrant programme 2018 for subscription of 349,000 shares of series B.

As of July 30, 2021, the total number of registered and outstanding shares of CELLINK amounts to 57,675,417, of which 1,500,000 are shares of series A and 56,175,417 are shares of series B, corresponding to a total of 71,175,417 votes. The share capital amounts to SEK 1,441,885.425. The company does not hold any treasury shares.

For further information, please contact:

Gusten Danielsson, CFO                            
Phone (US): +1 (857) 332 2138

Phone (Sweden): +46 709 91 86 04     
Email: gd@cellink.com
Isabelle Ljunggren, Head of Communications                            
Phone: +46 708 30 08 90

Email: il@cellink.com

This is information that CELLINK AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on July 30, 2021, at 08:00 a.m. (CEST).

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com 

CELLINK has initiated the process to change name from CELLINK to BICO to better reflect the company’s Group structure, strategy, bio convergence agenda and market position. Read more about the process for the name change in the press release that was sent out on July 7, 2021, www.cellink.com/investors/press-releases